These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 9694507

  • 1. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
    Blumenthal RD, Alisauskas R, Lew W, Sharkey RM, Goldenberg DM.
    Exp Hematol; 1998 Aug; 26(9):859-68. PubMed ID: 9694507
    [Abstract] [Full Text] [Related]

  • 2. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation.
    Blumenthal RD, Sharkey RM, Forman D, Wong G, Hess J, Goldenberg DM.
    Exp Hematol; 1995 Sep; 23(10):1088-97. PubMed ID: 7656929
    [Abstract] [Full Text] [Related]

  • 3. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
    Juweid ME, Blumenthal RD, Lew W, Hajjar G, Rubin AD, Goldenberg DM.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3337s-3342s. PubMed ID: 10541383
    [Abstract] [Full Text] [Related]

  • 4. Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice.
    Alisauskas RM, Goldenberg DM, Sharkey RM, Blumenthal RD.
    Int J Cancer; 1997 Jan 27; 70(3):323-9. PubMed ID: 9033635
    [Abstract] [Full Text] [Related]

  • 5. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.
    Blumenthal RD, Sharkey RM, Goldenberg DM.
    J Natl Cancer Inst; 1992 Mar 18; 84(6):399-407. PubMed ID: 1538418
    [Abstract] [Full Text] [Related]

  • 6. Cytokine intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF.
    Blumenthal RD, Sharkey RM, Forman D, Wong G, Goldenberg DM.
    Cancer; 1994 Feb 01; 73(3 Suppl):1083-92. PubMed ID: 8306251
    [Abstract] [Full Text] [Related]

  • 7. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD.
    J Nucl Med; 2003 Jan 01; 44(1):67-76. PubMed ID: 12515878
    [Abstract] [Full Text] [Related]

  • 8. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM.
    J Nucl Med; 1999 Oct 01; 40(10):1609-16. PubMed ID: 10520699
    [Abstract] [Full Text] [Related]

  • 9. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
    Blumenthal RD, Lew W, Juweid M, Alisauskas R, Ying Z, Goldenberg DM.
    Cancer; 2000 Jan 15; 88(2):333-43. PubMed ID: 10640965
    [Abstract] [Full Text] [Related]

  • 10. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R, Juweid M, Zhang CH, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [Abstract] [Full Text] [Related]

  • 11. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.
    Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM.
    Cancer Res; 1994 Jan 01; 54(1):142-51. PubMed ID: 8261435
    [Abstract] [Full Text] [Related]

  • 12. Use of hematopoietic growth factors to control myelosuppression caused by radioimmunotherapy.
    Blumenthal RD, Sharkey RM, Quinn LM, Goldenberg DM.
    Cancer Res; 1990 Feb 01; 50(3 Suppl):1003s-1007s. PubMed ID: 2404578
    [Abstract] [Full Text] [Related]

  • 13. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

  • 14. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
    Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 17. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 18. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 19. Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy.
    Blumenthal RD, Lew W, Reising A, Soyne D, Osorio L, Ying Z, Goldenberg DM.
    Int J Cancer; 2000 Apr 15; 86(2):276-80. PubMed ID: 10738257
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.